Current Report Filing (8-k)
July 16 2021 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 15, 2021
_________________________
Xenetic Biosciences, Inc.
(Exact name of registrant as specified in charter)
Nevada
|
001-37937
|
45-2952962
|
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
of incorporation)
|
|
Identification No.)
|
40 Speen Street, Suite 102
|
|
Framingham, Massachusetts
|
01701
|
(Address of principal executive offices)
|
(Zip Code)
|
(781) 778-7720
(Registrant’s telephone number, including
area code)
_________________________________________________
(Former name or former address, if changed since
last report)
Check the appropriate box below if
the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
XBIO
|
The Nasdaq Stock Market LLC
|
Purchase Warrants
|
XBIOW
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b) On
July 15, 2021, Dr. Dmitry Genkin resigned as a member of the Board of Directors of Xenetic Biosciences, Inc. (the “Company”).
Dr. Genkin’s decision to resign was not a result of any disagreement with the Company.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
XENETIC BIOSCIENCES, INC.
|
|
|
|
|
|
By: /s/ James Parslow
|
Date: July 16, 2021
|
Name: James Parslow
|
|
Title: Chief Financial Officer
|
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Jul 2023 to Jul 2024